Relation of GSTM1 Polymorphism with Leukemia / 中国实验血液学杂志

<p><b>OBJECTIVE</b>To investigate the relation of GSTM1 polymorphism in leukemia patients with therapeutic efficacy and the main biological characteristics.</p><p><b>METHODS</b>The GSTM1 genotypes were detected by nested PCR; the remission rate after 1 course of treatment and main biological characteristics at occurrence of leukemia were compared between AL patients with different GSTM1 genotypes, and their relation was analyzed.</p><p><b>RESULTS</b>The remission rate and partial remission rate after 1 course of treatment in patients with GSTM1-undeleted genotype were no significantly different from those in patients with GSTM1 null genotype (χ=0.290, P>0.05). The stratification analysis showed that GSTM1 null genotype was not related with age, sex, WBC count, Hb level, plt count at initial diagnosis and spleen enlargenent or no(P>0.05). The comparison of AML and ALL with GSTM1 null genotype by Log-rank showed that the survival rate was no statistically different between AML and ALL patients(χ=2.043, P>0.05), while the LDH level in serum of patients with GSTM1-undeleted genotype at initial diagnosis was statistically different from that in patients with GSTM1 null genotype (P=0.001).</p><p><b>CONCLUSION</b>The GSTM1 genotype does not relate with remission and partial remission rates after 1 course treatment of AL patients, but relates with LDH level. GSTM1 null genotype deletion may play a role in risk of leukemia.</p>

Preparation of molecular imprinted polymers for solid-phase extraction of L-tetrahydropalmatine / 中草药

Objective: To prepare the molecularly imprinted polymer (MIPs) of L-tetrahydropalmatine (L-THP) by the molecular imprinting technique and study on solid-phase extraction. Methods: Using L-THP as template, methyl acrylic acid (MAA) as functional monmer, and ehtylene glycol dimethacrylate (EDMA) as a cross-linking agent to prepare the L-THP-MIPs. A test was conducted to investigate the selectivity and the specificity of solid-phase extraction. Results: The experiment showed that the MIPs had the specific adsorption to L-THP, but did not have the specific adsorption to corydaline the structural analogue with L-THP. Conclusion: The L-THP-MIPs have a good selectivity and the specificity of L-THP.

Association of CD38 gene polymorphism with pathogenesis of chronic myeloid leukemia / 中国实验血液学杂志

This study was aimed to investigate the distribution of CD38 gene 184 locus allele frequency in chronic myeloid leukemia (CML) and its relation with genetic susceptibility of CML. 100 cases of CML were enrolled in patient group; 200 cases of nonhematologic diseases and nontumor diseases were enrolled in control group. The CD38 gene 184 locus polymorphism was detected by PCR-RFLP, the difference of genotypic frequencies in patient and control groups was analyzed by χ(2) test and Fisher exact probability test, the risk of genotype induced leukemia was expressed by odds ratio (OR) and 95% confidence interval (CI). The results showed that the distribution of CD38 gene 184 locus G/G, G/C, C/C genotypes was no significantly different between patients and control groups (p = 0.072). The wild type C/C was used as reference, the distribution of variant G/C genotype frequency in CML group was different statistically from control group (p = 0.032, OR value 0.517, 95%CI 0.283 - 0.947); the C allele frequency was used as reference, the G allele frequency in CML group was higher than that in control group (p = 0.028, OR value 0.597, 95%CI 0.377 - 0.94). It is concluded that the CD38 gene 184 locus G allele may be an protective gene against CML, and reduce the risk of CML relapse.

JAK2V617F mutation in the patients with myeloproliferative disorder and its relation with clinical characteristics / 中国实验血液学杂志

This study was aimed to investigate the incidence of JAK2V617F mutation in BCR-ABL negative patients with myeloproliferative disorders (MPD) and its relation with clinical characteristics of MPD. The sensitive and specific test for JAK2V617F mutation was established for improving diagnosis level in Gansu province. 47 BCR/ABL negative MPD patients and 12 healthy people were enrolled in this study. Allele specific polymerase chain reaction (AS-PCR) was used to amplify the exon 12 of JAK2 gene which harbours V617F mutation. The PCR products were identified by DNA sequencing. And its relation with clinical characteristics of MPD was analyzed also. The results indicated that the incidence of JAK2V617F positive mutation in 47 patients with BCR-ABL negative MPD was 74.5 % (35/47), including 83.9 %(26/31) in patients with polycythemia vera (PV), 60 % (9/15) in patients with essential thrombocythemia (ET), only in one patient with idiopathic myelofibrosis (IMF). In PV group, the patients with JAK2V617F positive mutation had higher counts of WBC and Plt than patients with JAK2V617F negative mutation. In ET group, the patients with JAK2V617F positive mutation had higher WBC count and Hb level than those in the patients with JAK2V617F negative mutation with tendency of suffering from complications such as hepatosplenomegaly, haemorrhage and thrombosis. It is concluded that JAK2V617F mutation is more frequent in BCR-ABL negative patients with MPD, the AS-PCR method is sensitive and specific for detection of the mutation and may successfully use in clinical examination.